Anaemia and the risk of progression from non-proliferative diabetic retinopathy to vision threatening diabetic retinopathy

被引:22
|
作者
Li, Yafeng [1 ]
Yu, Yinxi [2 ]
VanderBeek, Brian L. [1 ,3 ,4 ]
机构
[1] Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Ctr Prevent Ophthalmol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA
[3] Univ Penn, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA
[4] Univ Penn, Leonard Davis Inst, Perelman Sch Med, Philadelphia, PA 19104 USA
基金
美国国家卫生研究院;
关键词
BILLING CODES; MACULAR EDEMA; VISUAL-LOSS; HYPOXIA; HEMOGLOBIN; ACCURACY; CARE;
D O I
10.1038/s41433-019-0617-6
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background/Aims To determine if anaemia and oxygen delivery-related co-morbidities (ODCs) affect progression from non-proliferative diabetic retinopathy (NPDR) to vision-threatening diabetic retinopathy (VTDR). Methods This is a retrospective cohort study using medical claims data from a large US insurer. Cohorts were created from all NPDR patients between 2002 and 2016. Primary exclusion criteria consisted of any previous diagnosis of proliferative diabetic retinopathy (PDR), diabetic macular oedema (DME) or treatment used in the care of VTDR. The main outcome was a new diagnosis of VTDR (DME or PDR), PDR, or DME. A time-dependent, multivariate Cox proportional hazard regression was used to determine the association between anaemia and other ODCs with NPDR progression. Results Of the total 69,982 NPDR patients included for analysis, 12,270, 2,162, and 10,322 progressed to VTDR, PDR and DME, respectively. Both mild and moderate/severe (mod/sev) anaemia were associated with an increased hazard for progression to VTDR (mild HR:1.10, 95% CI:1.04-1.16, p < 0.001; mod/sev HR:1.20, 95% CI:1.12-1.29, p < 0.001), PDR (mild HR:1.29, 95% CI:1.13-1.46, p < 0.001; mod/sev HR:1.43, 95% CI:1.21-1.69, p < 0.001), and DME (mild HR:1.06, 95% CI:1.00-1.13, p < 0.001; mod/sev HR:1.14, 95% CI:1.05-1.24, p < 0.001). ODCs such as chronic pulmonary disease and history of blood disorder/cancer were also significantly associated with an increased hazard for NPDR progression (HR > 1.00, p < 0.001 for all comparisons). Conclusions Anaemia, independent of kidney disease, appears to play a significant role in progression from NPDR to VTDR, PDR, or DME. Concurrently, association of ODCs with NPDR progression lends support to the underlying mechanisms of anaemia in the pathogenesis of diabetic retinopathy.
引用
收藏
页码:934 / 941
页数:8
相关论文
共 50 条
  • [21] Treatment effects of captopril on non-proliferative diabetic retinopathy
    WANG Ning
    ZHENG Zhi
    JIN Hui-yi
    XU Xun
    中华医学杂志(英文版), 2012, (02) : 287 - 292
  • [22] Aqueous Humor Cytokines in Non-Proliferative Diabetic Retinopathy
    Obada, Otilia
    Pantalon, Anca Delia
    Rusu-Zota, Gabriela
    Haisan, Anca
    Lupusoru, Smaranda Ioana
    Constantinescu, Daniela
    Chiselita, Dorin
    MEDICINA-LITHUANIA, 2022, 58 (07):
  • [23] Characterization of real-world progression from non-proliferative to proliferative diabetic retinopathy in patients with diabetes
    Babiuch, Amy
    Gale, Sara L.
    Conti, Thais F.
    McLaughlin, Lucas
    Kalur, Aneesha
    Gan, Ryan
    Iyer, Amogh
    Ferrara, Daniela
    Greenlee, Tyler
    Spicer, Galin Jackson
    Muste, Justin
    Hopkins, Jill Jill
    Singh, Rishi P.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [24] Fenofibrate and Statin Use and the Risk of Progression to Vision Threatening Diabetic Retinopathy
    VanderBeek, Brian L.
    Bavinger, J. Clay
    Yu, Yinxi
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [25] Prevalence of diabetic retinopathy, proliferative diabetic retinopathy and non-proliferative diabetic retinopathy in Asian T2DM patients: a systematic review and Metaanalysis
    Qian-Hui Yang
    Yan Zhang
    Xiao-Min Zhang
    Xiao-Rong Li
    International Journal of Ophthalmology, 2019, (02) : 302 - 311
  • [26] Progression to Proliferative Diabetic Retinopathy in the Danish Registry of Diabetic Retinopathy
    Dinesen, S.
    Stokholm, L.
    Peto, T.
    Savarimuthu, T. R.
    Grauslund, J.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2021, 31 (2_SUPPL) : 25 - 25
  • [27] Proteomic Analysis of the Vitreous Body in Proliferative and Non-Proliferative Diabetic Retinopathy
    Van-An Duong
    Ahn, Jeeyun
    Han, Na-Young
    Park, Jong-Moon
    Mok, Jeong-Hun
    Kim, Tae Wan
    Lee, Hookeun
    CURRENT PROTEOMICS, 2021, 18 (02) : 143 - 152
  • [28] Treatment of non-proliferative diabetic retinopathy with defibrotide in NIDDM patients
    Grenga, R
    Giusti, C
    DeMattia, G
    Vingolo, EM
    Laurenti, O
    Pannarale, MR
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1997, 38 (04) : 1629 - 1629
  • [29] Meibomian Gland Dysfunction and Dropout in Diabetic Patients with Non-Proliferative Diabetic Retinopathy
    Mohamed-Noriega, Karim
    Gonzalez-Arocha, Carla Sofia
    Morales-Wong, Fernando
    Velasco-Sepulveda, Braulio Hernan
    Rodriguez-Cuevas, Jonathan Octavio
    Cepeda-Ortegon, Gerardo Esteban
    Corral-Benavides, Sergio Antonio
    Martinez-Delgado, Jose Francisco
    Mohamed-Noriega, Jibran
    Fernandez-De-Luna, Marissa L.
    Mohamed-Hamsho, Jesus
    BIOENGINEERING-BASEL, 2024, 11 (09):
  • [30] A NEW CLASSIFICATION SCHEME OF NON-PROLIFERATIVE DIABETIC-RETINOPATHY
    FREYLER, H
    KLEMEN, U
    PRSKAVEC, F
    SCHEIMBAUER, I
    ALBRECHT VON GRAEFES ARCHIV FUR KLINISCHE UND EXPERIMENTELLE OPHTHALMOLOGIE, 1981, 217 (01): : 69 - 78